Latest Antiplatelet drugs Stories
LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination carries a greater risk of gastrointestinal bleeding.
Parker Waichman LLP has filed a lawsuit on behalf of a man who experienced hemorrhaging, allegedly due to the use of Plavix (clopidogrel).
Parker Waichman LLP has filed a lawsuit on behalf of an Arizona woman who took Plavix (clopidogrel) and suffered from two gastrointestinal hemorrhages.
Parker Waichman LLP has filed three lawsuits on behalf of the estates of victims who suffered fatal gastrointestinal and/or cerebral hemorrhaging allegedly due to the blood thinner, Plavix.
Researchers report no significant difference in high versus low dose aspirin in preventing recurring cardiovascular events.
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of the arteries.
The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association’s International Stroke Conference 2012.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.